Manufacturer of Controlled Substances; Notice of Registration, 56614-56615 [E8-22877]

Download as PDF 56614 Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule mstockstill on PROD1PC66 with NOTICES Methcathinone (1237) .................................................................................................................................................................................. N-Ethylamphetamine (1475) ........................................................................................................................................................................ N,N-Dimethylamphetamine (1480) ............................................................................................................................................................... 4-Methylaminorex (cis isomer) (1590) ......................................................................................................................................................... Alpha-ethyltryptamine (7249) ....................................................................................................................................................................... Lysergic acid diethylamide (7315) ............................................................................................................................................................... 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) ................................................................................................................................ Tetrahydrocannabinols (7370) ..................................................................................................................................................................... Mescaline (7381) .......................................................................................................................................................................................... 4-Bromo-2,5-dimethoxyamphetamine (7391) ............................................................................................................................................... 4-Bromo-2,5-dimethoxyphenethylamine (7392) ........................................................................................................................................... 4-Methyl-2,5-dimethoxyamphetamine (7395) ............................................................................................................................................... 2,5-Dimethoxyamphetamine (7396) ............................................................................................................................................................. 2,5-Dimethoxy-4-ethylamphetamine (7399) ................................................................................................................................................. 3,4-Methylenedioxyamphetamine (7400) ..................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ................................................................................................................................... 3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................ 3,4-Methylenedioxymethamphetamine (MDMA) (7405) .............................................................................................................................. 4-Methoxyamphetamine (7411) ................................................................................................................................................................... Alpha-methyltryptamine (7432) .................................................................................................................................................................... Bufotenine (7433) ......................................................................................................................................................................................... Diethyltryptamine (7434) .............................................................................................................................................................................. Dimethyltryptamine (7435) ........................................................................................................................................................................... Psilocybin (7437) .......................................................................................................................................................................................... Psilocyn (7438) ............................................................................................................................................................................................. 5-Methoxy-N,N-diisopropyltryptamine (7439) ............................................................................................................................................... N-Ethyl-1-phenylcyclohexylamine (7455) ..................................................................................................................................................... 1-(1-Phenylcyclohexyl)pyrrolidine (7458) ..................................................................................................................................................... 1-Phenylcyclohexylamine (7460) ................................................................................................................................................................. 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ................................................................................................................................................ Normorphine (9313) ..................................................................................................................................................................................... Methamphetamine (1105) ............................................................................................................................................................................ Phencyclidine (7471) .................................................................................................................................................................................... Phenylacetone (8501) .................................................................................................................................................................................. 1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................. Cocaine (9041) ............................................................................................................................................................................................. Codeine (9050) ............................................................................................................................................................................................. Dihydrocodeine (9120) ................................................................................................................................................................................. Dihydromorphine (9145) ............................................................................................................................................................................... Ecgonine (9180) ........................................................................................................................................................................................... Meperidine intermediate-B (9233) ................................................................................................................................................................ Noroxymorphone (9668) .............................................................................................................................................................................. The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Alltech Associates, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Alltech Associates Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, VerDate Aug<31>2005 16:59 Sep 26, 2008 Jkt 214001 the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: September 22, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–22875 Filed 9–26–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated April 28, 2008 and published in the Federal Register on May 2, 2008 (73 FR 24313), Lin Zhi International Inc., 687 North Pastoria PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug ....................................................... Tetrahydrocannabinols (7370) ..... 3,4-Methylenedioxymethamphetamine (MDMA) (7405). Cocaine (9041) ............................. Oxycodone (9143) ........................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Schedule I I II II II II II II The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing. E:\FR\FM\29SEN1.SGM 29SEN1 Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lin Zhi International Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lin Zhi International Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: September 22, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–22877 Filed 9–26–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on PROD1PC66 with NOTICES Manufacturer of Controlled Substances; Notice of Registration By Notice dated May 15, 2008 and published in the Federal Register on May 27, 2008 (73 FR 30418), Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Oripavine (9330), a basic class of controlled substance listed in schedule II. The company will use the above listed controlled substance in the manufacture of other controlled substance intermediates for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Siegfried (USA), Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Siegfried (USA), Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the VerDate Aug<31>2005 16:48 Sep 26, 2008 Jkt 214001 company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: September 22, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–22879 Filed 9–26–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Occupational Safety and Health Administration [Docket No. OSHA–2008–0023] Telecommunications; Extension of the Office of Management and Budget’s (OMB) Approval of Information Collection (Paperwork) Requirements Occupational Safety and Health Administration (OSHA), Labor. ACTION: Request for public comment. AGENCY: SUMMARY: OSHA solicits comments concerning its proposal to extend OMB approval of the information collection requirement contained in the Standard on Telecommunications (29 CFR 1910.268). The purpose of this requirement is to ensure that employees have been trained as required by the Standard to prevent risk of death or serious injury. DATES: Comments must be submitted (postmarked, sent, or received) by November 28, 2008. ADDRESSES: Electronically: You may submit comments and attachments electronically at https:// www.regulations.gov, which is the Federal eRulemaking Portal. Follow the instructions online for submitting comments. Facsimile: If your comments, including attachments, are not longer than 10 pages, you may fax them to the OSHA Docket Office at (202) 693–1648. Mail, hand delivery, express mail, messenger, or courier service: When using this method, you must submit three copies of your comments and attachments to the OSHA Docket Office, Docket No. OSHA–2008–0023, U.S. Department of Labor, Occupational Safety and Health Administration, Room N–2625, 200 Constitution Avenue, NW., Washington, DC 20210. Deliveries (hand, express mail, PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 56615 messenger, and courier service) are accepted during the Department of Labor’s and Docket Office’s normal business hours, 8:15 a.m. to 4:45 p.m., e.t. Instructions: All submissions must include the Agency name and OSHA docket number for the ICR (OSHA– 2008–0023). All comments, including any personal information you provide, are placed in the public docket without change, and may be made available online at https://www.regulations.gov. For further information on submitting comments see the ‘‘Public Participation’’ heading in the section of this notice titled ‘‘SUPPLEMENTARY INFORMATION.’’ Docket: To read or download comments or other material in the docket, go to https://www.regulations.gov or the OSHA Docket Office at the address above. All documents in the docket (including this Federal Register notice) are listed in the https:// www.regulations.gov index; however, some information (e.g., copyrighted material) is not publicly available to read or download through the Web site. All submissions, including copyrighted material, are available for inspection and copying at the OSHA Docket Office. You may also contact Theda Kenney at the address below to obtain a copy of the ICR. FOR FURTHER INFORMATION CONTACT: Theda Kenney or Todd Owen, Directorate of Standards and Guidance, OSHA, U.S. Department of Labor, Room N–3609, 200 Constitution Avenue, NW., Washington, DC 20210; telephone (202) 693–2222. SUPPLEMENTARY INFORMATION: I. Background The Department of Labor, as part of its continuing effort to reduce paperwork and respondent (i.e., employer) burden, conducts a preclearance consultation program to provide the public with an opportunity to comment on proposed and continuing information collection requirements in accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3506(c)(2)(A)). This program ensures that information is in the desired format, reporting burden (time and costs) is minimal, collection instruments are clearly understood, and OSHA’s estimate of the information collection burden is accurate. The Occupational Safety and Health Act of 1970 (the OSH Act) (29 U.S.C. 651 et seq.) authorizes information collection by employers as necessary or appropriate for enforcement of the Act or for developing information regarding the causes and prevention of E:\FR\FM\29SEN1.SGM 29SEN1

Agencies

[Federal Register Volume 73, Number 189 (Monday, September 29, 2008)]
[Notices]
[Pages 56614-56615]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-22877]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated April 28, 2008 and published in the Federal 
Register on May 2, 2008 (73 FR 24313), Lin Zhi International Inc., 687 
North Pastoria Avenue, Sunnyvale, California 94085, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
                                             ...........................
Tetrahydrocannabinols (7370)...............  I
3,4-Methylenedioxymetham-phetamine (MDMA)    I
 (7405).
Cocaine (9041).............................  II
Oxycodone (9143)...........................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
as bulk reagents for use in drug abuse testing.

[[Page 56615]]

    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Lin Zhi International Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Lin Zhi International Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

     Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-22877 Filed 9-26-08; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.